Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.19M | $31.0M | $15.6M | $9.16M | $3.50M | $800K |
| Revenue growth | — | 237.0% | -49.6% | -41.3% | -61.8% | -77.1% |
| Operating income | -$44.5M | -$34.1M | -$70.9M | -$75.4M | -$37.0M | -$48.5M |
| Operating margin | -484.2% | -110.2% | -454.0% | -823.3% | -1057.1% | -6056.4% |
| Net income | -$44.3M | -$34.1M | -$68.8M | -$68.2M | -$36.6M | -$45.3M |
| Net margin | -481.4% | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| EPS (diluted) | -$16.00 | -$1.22 | -$1.90 | -$1.63 | -$22.10 | -$9.64 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$37.8M | -$60.3M | -$74.1M | -$79.7M | -$21.3M | -$47.8M |
| Capital expenditures | $766K | $1.76M | $1.43M | $414K | — | — |
| Free cash flow | -$38.6M | -$62.0M | -$75.5M | -$80.2M | — | — |
| Share buybacks | — | — | — | $663K | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $162M | $232M | $59.9M | $120M | $12.1M | $94.5M |
| Total assets | $168M | $248M | $172M | $192M | $15.9M | $153M |
| Total liabilities | $63.5M | $40.0M | $25.3M | $22.3M | $17.4M | $19.8M |
| Shareholders' equity | -$101M | $208M | $147M | -$126M | -$161M | $133M |
| Retained earnings | -$111M | -$145M | -$214M | -$282M | -$180M | -$230M |
| Shares (wtd avg diluted) | 3.10M | 28.0M | 36.2M | 41.7M | 1.19M | 4.87M |
Every figure is extracted from ImageneBio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.